Britain’s AstraZeneca has agreed to buy US drugmaker Alexion Pharmaceuticals for $39 billion in cash and shares to bolster its positions in immunology and rare diseases.
AstraZeneca, one of the frontrunners in the drugs industry’s search for a Covid-19 vaccine, said Alexion shareholders would receive $60 in cash and 2.1243 AstraZeneca ADSs for each Alexion share.
Based on a reference average ADR price of $54.14, that implies a total price of $175 per share.
Alexion shares closed at around $121 apiece on Friday. “This acquisition allows us to enhance our presence in immunology,” said AstraZeneca Chief Executive Pascal Soriot said in a statement.
“Alexion has established itself as a leader in complement biology, bringing life-changing benefits to patients with rare diseases.”
The British company said the boards of both companies had approved the deal which, subject to regulatory and shareholder approval, is expected to close in the third quarter of 2021
Published on December 12, 2020
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.